The Incidence, Risk Factors and Clinical Course of De Novo Hepatitis B Infection in Pediatric Living Donor Liver Transplantation.
Pediatric Gastroenterology, Baskent University, Ankara, Turkey
Pediatric Gastroenterology, Baskent University, Ankara, Turkey
Department of General Surgery, Baskent University, Ankara, Turkey
Department of General Surgery, Baskent University, Ankara, Turkey.
Meeting: 2016 American Transplant Congress
Abstract number: D206
Keywords: Hepatitis B, Liver
Session Information
Session Name: Poster Session D: Pediatric Liver Transplantation
Session Type: Poster Session
Date: Tuesday, June 14, 2016
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Halls C&D
Aim: We evaluated the incidence, risk factors and clinical course of liver transplanted pediatric patients with de novo hepatitis B infection and the clinical course of liver transplanted pediatric patients from anti HBc IgG positive donors.
Methods: We retrospectively collected the data of children who underwent liver transplantation between 2000-2015 in Baskent University Hospital and developed de novo hepatitis B infection or who had anti HBc IgG positive living donors. Patients who had a follow up period of minimum 18 months were enrolled.
Results: There were a total of 25 patients, 10 of whom had de novo hepatitis B infection. Twelve (48%) patients were female. Patients were between 173,32±79,83 months old (min-max: 36-300 months).
Patients with and without de novo hepatitis B infection were compared. The number of HBV immunizations (preoperative HBV vaccine doses) were significantly lower in patients with de novo hepatitis B infection (0,9±1,1 vaccine dose) when compared with the number of HBV immunizations in patients without de novo hepatitis B infection (2,67±0,86 vaccine dose), p=0,001. Preoperative anti HBs positivity were significantly lower in patients with de novo hepatitis B infection when compared with preoperative anti HBs positivity in patients without de novo hepatitis B infection, p=0,012).
The clinical and laboratory features of patients with de novo hepatitis B infection were evaluated. The mean HBs Ag titers and mean HBV DNA titers of patients with de novo hepatitis B infection at the time of diagnosis were 954,55±1520,2 IU/ml (min-max: 17,7-3968 IU/ml) and 581,68±1369,03.106copy/ml (min-max: 0-4200.106copy/ml) respectively. Three patients with de novo hepatitis B infection had anti HBc IgG negative living donors.
Three (30%) of the patients with de novo hepatitis B infection had HBs Ag clearence at 10±7 months (min-max:3-17 months) and one patient had HBV DNA clearence and anti HBe positivity at 114 months.
Conclusion: The number of HBV immunizations and preoperative anti HBs positivity were important risk factors for development of de novo hepatitis B infection.
CITATION INFORMATION: Baris Z, Ozcay F, Moray G, Haberal M. The Incidence, Risk Factors and Clinical Course of De Novo Hepatitis B Infection in Pediatric Living Donor Liver Transplantation. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:
Baris Z, Ozcay F, Moray G, Haberal M. The Incidence, Risk Factors and Clinical Course of De Novo Hepatitis B Infection in Pediatric Living Donor Liver Transplantation. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/the-incidence-risk-factors-and-clinical-course-of-de-novo-hepatitis-b-infection-in-pediatric-living-donor-liver-transplantation/. Accessed May 11, 2025.« Back to 2016 American Transplant Congress